A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin

Area of Science:

• Pharmacology
• Genetics
• Molecular Biology

Background:

• Aminoglycosides are prototypic agents for translational bypass therapy (TBT).
• Existing methods lack quantitative assessment of TBT efficacy in vivo.
• There is a need for more potent drugs and robust in vivo models.

Purpose of the Study:

• To develop and validate an in vivo system for quantitative assessment of premature stop codon management therapies.
• To compare the efficacy of geneticin and gentamicin in vivo using the developed system.

Main Methods:

• Development of the in vivo quantitative stop codon management repli-sampling TBT efficacy assay (IQSCMaRTEA).
• Quantitative assessment of drug efficacy in an in vivo model system.

Main Results:

• Geneticin demonstrated significantly higher efficacy in vivo compared to gentamicin.
• Geneticin treatment resulted in a multiday response, with detectable F9 antigen after 3 weeks.
• The IQSCMaRTEA system proved useful for evaluating drugs that bypass nonsense mutations.

Conclusions:

• The IQSCMaRTEA system is a valuable tool for evaluating drugs targeting nonsense mutations.
• Geneticin shows promise as a treatment for genetic diseases caused by nonsense mutations, warranting further investigation of its analogues.
• The system may also aid in testing inhibitors of nonsense-mediated decay for combined therapeutic strategies.